Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RSA launches new "escalator management" recruitment

This article was originally published in Scrip

Executive Summary

The life sciences recruitment company RSA has introduced its "escalator management" staffing initiative. The company's chief executive Nick Stephens launched the approach in Singapore, when he also announced the new RSA Singapore interim management division. The process relies on experts and specialist teams being brought into a business, either at short notice or for longer periods depending on the company's demands. For example, a new biotech company may begin with a chief scientific officer heading up the drug discovery phase, followed by a clinical development officer, a chief medical officer and then a business development director working on the licensed product. Mr Stephens said: "One of the fundamental problems a new company faces is that taking on staff permanently is costly and time-consuming, and in a changing environment, a permanent person with a fixed set of skills may not be what is needed. As the company enters a new phase, it needs access to different skills."



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts